CCL

Összesen 25 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM133708
Első szerző:Árokszállási Tamás (neurológus)
Cím:Elevated Blood Alcohol Concentration at Stroke Onset Predicts Poor Clinical Outcomes and Mortality After Intracerebral Hemorrhage : a Retrospective Cohort Study / Tamás Árokszállási, Attila Nagy, Eszter Balogh, Edit Boglárka Nagy, Máté Sik, Zsófia Fülesdi, Rita Orbán-Kálmándi, Anita Árokszállási, Péter Juhász, Gábor Fekete, Lilla Rácz, Tünde Csépány, László Csiba, Zsuzsa Bagoly, László Oláh
Dátum:2026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Neurology and Therapy. - 15 : 1 (2026), p. 287-307. -
További szerzők:Nagy Attila Csaba (1981-) (megelőző orvostan és népegészségtan szakorvos, epidemiológus) Balogh Eszter (1991-) (neurológus) Nagy Edit Boglárka Sik Máté (1991-) (általános orvos) Fülesdi Zsófia (1990-) (radiológus) Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Árokszállási Anita (1982-) (orvos) Juhász Péter (1987-) Fekete Gábor (1979-) (idegsebész) Rácz Lilla Csépány Tünde (1956-) (neurológus, pszichiáter) Csiba László (1952-) (neurológus, pszichiáter) Bagoly Zsuzsa (1978-) (orvos) Oláh László (1967-) (neurológus)
Pályázati támogatás:MTA-DE Lendület 423 "Momentum" Hemostasis and Stroke Research Group
MTA
HUN-REN DE Cerebrovascular Research Group
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM050853
035-os BibID:PMID:23293933
Első szerző:Bánáti Miklós (neurológus, Pécs)
Cím:Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system / M. Banati, P. Csecsei, E. Koszegi, H. H. Nielsen, G. Suto, L. Bors, A. Trauninger, T. Csepany, C. Rozsa, G. Jakab, T. Molnar, A. Berthele, S. R. Kalluri, T. Berki, Z. Illes
Dátum:2013
ISSN:1351-5101
Megjegyzések:Antibodies against gastrointestinal antigens may indicate altered microbiota and immune responses in the gut. Recent experimental data suggest a connection between gastrointestinal immune responses and CNS autoimmunity. METHODS: Antibodies against gliadin, tissue transglutaminase (tTG), intrinsic factor (IF), parietal cells (PC) and Saccharomyces cerevisiae (ASCA) were screened in the sera of 45 patients with AQP4-seropositive neuromyelitis optica (NMO) and NMO spectrum diseases (NMO/NMO-SD), 17 patients with AQP4-seronegative NMO, 85 patients with clinically definite multiple sclerosis (MS), and 48 healthy controls (HC). RESULTS: Thirty-seven percentages of patients with AQP4-seropositive NMO/NMO-SD and 28% of patients with MS had at least one particular antibody in contrast to 8% of HC (P < 0.01, respectively). Antibodies were most common (46%) in AQP4-seropositive myelitis (P = 0.01 versus HS, P = 0.05 versus MS). Anti-gliadin and ASCA were more frequent in the AQP4-seropositive NMO-spectrum compared to controls (P = 0.01 and P < 0.05, respectively). CONCLUSION: Antibody responses against gastrointestinal antigens are common in MS and AQP4-seropositive NMO/NMO-SD, especially in longitudinally extensive myelitis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
anti-Saccharomyces cerevisiae
aquaporin 4
gliadin
intrinsic factor
multiple sclerosis
myelitis
neuromyelitis optica
optic neuritis
parietal cell
transglutaminase
Megjelenés:European Journal of Neurology. - 20 : 11 (2013), p. 1492-1495. -
További szerzők:Csécsei Péter (1992-) (neurológus) Kőszegi E. (neurológus, Pécs) Nielsen, Helle H. Sütő Gábor Bors László (Neurológus, Pécs) Trauninger Anita (Pécs orvos) Csépány Tünde (1956-) (neurológus, pszichiáter) Rózsa Csilla Jakab Gabriella Molnár T. Berthele, A. Kalluri, Sudhakar Reddy Berki Tímea Illés Zsolt (neurológus, Pécs)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM132948
035-os BibID:(scopus)105011883480 (wos)001538131900001
Első szerző:Cortese, Marianna
Cím:Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression / Cortese Marianna, Peng Xiaojing, Edan Gilles, Freedman Mark S., Hartung Hans-Peter, Montalban Xavier, Sandbrink Rupert, Radü Ernst-Wilhelm, Barkhof Frederik, Wicklein Eva-Maria, Kappos Ludwig, Ascherio Alberto, Bjornevik Kjetil, BENEFIT Study Group
Dátum:2025
ISSN:0028-3878 1526-632X
Megjegyzések:Background and Objectives Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. Methods This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. Results We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39?0.95) and 0.60 (95% CI 0.37?0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38?0.94) and 0.65 (95% CI 0.43?0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. Discusssion Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Neurology. - 105 : 3 (2025), p. 1-11. -
További szerzők:Peng, Xiaojing Edan, Gilles Freedman, Mark S. Hartung, Hans-Peter Montalbán, Xavier Sandbrink, Rupert Radü, Ernst-Wilhelm Barkhof, Frederik Wicklein, Eva-Maria Kappos, Ludwig Ascherio, Alberto Bjornevik, Kjetil Csépány Tünde (1956-) (neurológus, pszichiáter) Csiba László (1952-) (neurológus, pszichiáter) BENEFIT Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM032363
Első szerző:Csépány Tünde (neurológus, pszichiáter)
Cím:MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension / Csepany, T., Bereczki, D., Kollar, J., Sikula, J., Kiss, E., Csiba, L.
Dátum:2003
Megjegyzések:Involvement of the brain is one of the most important complications of systemic lupus erythematosus (SLE). To investigate the correlation between abnormal cranial MRI findings and age, duration of SLE, neuropsychiatric (NP) manifestations, hypertensive status, and the presence of antiphospholipid antibodies (PA) in patients with SLE we evaluated the MRI results of 81 SLE patients in nine NP clinical subgroups.Immunoserological status was described by the presence of lupus anticoagulant (LA), and anticardiolipin antibodies (aCL). The MRI findings were categorized as normal [41], cerebral atrophy [15], small subcortical hyperintensity [7], and infarct larger than 10mm [18]. Mean age differed among the clinical subgroups (ANOVA, p = 0.002), whereas there was no age difference among the subgroups based on MRI and immunoserological results. Patients with hypertension (33/81) were a mean of 6 years older at the time of examination (p = 0.033) and had stroke more frequently, than normotensive ones (p = 0.0015). MRI abnormalities were more frequent in patients with LA positivity (p < 0.01) than in those without these antibodies, and in the hypertensive than in the normotensive subgroup (p = 0.00041). The presence of PA was associated with abnormal MRI even after controlling for the effect of age and hypertensive status (p = 0.011). In our study the MRI findings in central nervous system SLE were independent of the age of patients and the age at the diagnosis of SLE, and were not influenced by the duration of SLE; however, they were associated with immunoserological parameters and hypertension.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
multiple sclerosis
autoimmunity
iron
prolactin
ferritin
Megjelenés:Journal of Neurology. - 250 : 11 (2003), p. 1348-1354. -
További szerzők:Bereczki Dániel (1960-) (neurológus) Kollár József (1950-) (radiológus) Sikula Judit (1954-) (radiológus) Kiss Emese (1960-) (belgyógyász, immunológus) Csiba László (1952-) (neurológus, pszichiáter)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM015606
035-os BibID:15258802
Első szerző:Csépány Tünde (neurológus, pszichiáter)
Cím:Miller Fisher syndrome : a presenting clinical manifestation of lung cancer in apreviously apparently healthy individual / Tunde Csepany, Judit Boczan, Maria T. Magyar, Sandor Molnar, Laszlo Csiba, Judit Decsy, Judit Toth, Szabolcs Felszeghy, Szabolcs Szakall, Zsolt Szentkereszty, Daniel Bereczki
Dátum:2004
ISSN:0340-5354 (Linking)
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztői levél
0 (KRT7 protein, human)
0 (Keratin-7)
0 (Tumor Markers, Biological)
68238-35-7 (Keratins)
Adenocarcinoma/*secondary
Brain/pathology/physiopathology
Brain Neoplasms/*secondary
Cerebrospinal Fluid/cytology
Diagnosis, Differential
Facial Nerve/pathology/physiopathology
Humans
Keratin-7
Keratins/metabolism
Lateral Ventricles/pathology
Lung/pathology/physiopathology
Lung Neoplasms/*pathology
Male
Meningeal Neoplasms/secretion
Middle Aged
Miller Fisher Syndrome/cerebrospinal fluid/*etiology/pathology
egyetemen (Magyarországon) készült közlemény
Oculomotor Nerve/pathology/physiopathology
Tumor Markers, Biological/metabolism
Megjelenés:Journal of Neurology. - 251 : 7 (2004), p. 898-900. -
További szerzők:Boczán Judit (1972-) (neurológus) Magyar Mária Tünde (1970-) (neurológus) Molnár Sándor (1973-) (neurológus) Csiba László (1952-) (neurológus, pszichiáter) Décsy Judit Tóth Judit (1964-) (radiológus) Felszeghy Szabolcs Béla (1972-) (fogorvos, anatómus, kötőszövetbiológus) Szakáll Szabolcs Szentkereszty Zsolt (1961-) (sebész) Bereczki Dániel (1960-) (neurológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
elektronikus elérés
Borító:

6.

001-es BibID:BIBFORM126270
035-os BibID:(scopus)85190160325 (wos)001201473600001
Első szerző:Dekeyser, Cathérine
Cím:Routine CSF parameters as predictors of disease course in multiple sclerosis : an MSBase cohort study / Dekeyser C., Hautekeete M., Cambron M., Van Pesch V., Patti F., Kuhle J., Khoury S., Lechner Scott J., Gerlach O., Lugaresi A., Maimone D., Surcinelli A., Grammond P., Kalincik T., Habek M., Willekens B., Macdonell R., Lalive P., Csepany T., Butzkueven H., Boz C., Tomassini V., Foschi M., Sánchez-Menoyo J. L., Altintas A., Mrabet S., Iuliano G., Sa M. J., Alroughani R., Karabudak R., Aguera-Morales E., Gray O., de Gans K., van der Walt A., McCombe P. A., Deri N., Garber J., Al-Asmi A., Skibina O., Duquette P., Cartechini E., Spitaleri D., Gouider R., Soysal A., Van Hijfte L., Slee M., Amato M. P., Buzzard K., Laureys G.
Dátum:2024
ISSN:0022-3050 1468-330X
Megjegyzések:Background: It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course. Methods: This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis. Results: In total, 11 245 participants were included of which 93.7% (n=10 533) were persons with relapsing-remitting MS (RRMS). In RRMS, the presence of CSF oligoclonal bands (OCBs) was associated with shorter time to disability milestones EDSS 4 (adjusted HR=1.272 (95% CI, 1.089 to 1.485), p=0.002), EDSS 6 (HR=1.314 (95% CI, 1.062 to 1.626), p=0.012) and EDSS 7 (HR=1.686 (95% CI, 1.111 to 2.558), p=0.014). On the other hand, the presence of CSF pleocytosis (?5 cells/?L) increased time to moderate disability (EDSS 4) in RRMS (HR=0.774 (95% CI, 0.632 to 0.948), p=0.013). None of the CSF variables were associated with time to disability milestones in persons with primary progressive MS (PPMS). The presence of CSF pleocytosis increased ARR2 in RRMS (adjusted R2=0.036, p=0.015). Conclusions: In RRMS, the presence of CSF OCBs predicts shorter time to disability milestones, whereas CSF pleocytosis could be protective. This could however not be found in PPMS. CSF pleocytosis is associated with short-term inflammatory disease activity in RRMS. CSF analysis provides prognostic information which could aid in clinical and therapeutic decision-making.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
CLINICAL NEUROLOGY
CSF
MULTIPLE SCLEROSIS
NEUROIMMUNOLOGY
Megjelenés:Journal of Neurology, Neurosurgery, and Psychiatry . - 95 : 11 (2024), p. 1021-1031. -
További szerzők:Hautekeete, Matthias Cambron, Melissa Pesch, Vincent van Patti, Francesco Kuhle, Jens Khoury, Samia J. Lechner Scott, Jeanette Gerlach, Oliver Lugaresi, Alessandra Maimone, Davide Surcinelli, Andrea Grammond, Pierre Kalincik, Tomas Habek, Mario Willekens, Barbara Macdonell, Richard Lalive, Patrice H. Csépány Tünde (1956-) (neurológus, pszichiáter) Butzkueven, Helmut Boz, Cavit Tomassini, Valentina Foschi, Matteo Sanchez-Menoyo, Jose Altintas, Ayse Mrabet, Saloua Iuliano, Gerardo Sá, Maria José Alroughani, Raed Karabudak, Rana Aguera-Morales, Eduardo Gray, Orla de Gans, Koen Walt, Anneke van der McCombe, Pamela Deri, Norma Garber, Justin Al-Asmi, Abdullah Skibina, Olga Duquette, Pierre Cartechini, Elisabetta Spitaleri, Daniele Gouider, Riadh Soysal, Aysun Van Hijfte, Liesbeth Slee, Mark Amato, Maria Pia Buzzard, Katherine Laureys, Guy
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM119146
035-os BibID:(scopus)85177103067 (wos)001030569800001
Első szerző:Diouf, Ibrahima
Cím:Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis : causal inference to emulate a multiarm randomised trial / Diouf Ibrahima, Malpas Charles B., Sharmin Sifat, Roos Izanne, Horakova Dana, Kubala Havrdova Eva, Patti Francesco, Shaygannejad Vahid, Ozakbas Serkan, Eichau Sara, Onofrj Marco, Lugaresi Alessandra, Alroughani Raed, Prat Alexandre, Duquette Pierre, Terzi Murat, Boz Cavit, Grand'Maison Francois, Sola Patrizia, Ferraro Diana, Grammond Pierre, Yamout Bassem, Altintas Ayse, Gerlach Oliver, Lechner-Scott Jeannette, Bergamaschi Roberto, Karabudak Rana, Iuliano Gerardo, McGuigan Christopher, Cartechini Elisabetta, Hughes Stella, Sa Maria Jose, Solaro Claudio, Kappos Ludwig, Hodgkinson Suzanne, Slee Mark, Granella Franco, de Gans Koen, McCombe Pamela A., Ampapa Radek, van der Walt Anneke, Butzkueven Helmut, Sánchez-Menoyo José Luis, Vucic Steve, Laureys Guy, Sidhom Youssef, Gouider Riadh, Castillo-Trivino Tamara, Gray Orla, Aguera-Morales Eduardo, Al-Asmi Abdullah, Shaw Cameron, Al-Harbi Talal M., Csepany Tunde, Sempere Angel P., Trevino Frenk Irene, Stuart Elizabeth A., Kalincik Tomas
Dátum:2023
ISSN:0022-3050
Megjegyzések:Background Simultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. Here we emulate a randomised trial simultaneously comparing the effectiveness of six commonly used therapies over 5 years. Methods Data from 74 centres in 35 countries were sourced from MSBase. For each patient, the first eligible intervention was analysed, censoring at change/discontinuation of treatment. The compared interventions included natalizumab, fingolimod, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate and no treatment. Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement. Results 23 236 eligible patients were diagnosed with RRMS or clinically isolated syndrome. Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). Further, natalizumab (HR=0.43, 95% CI=0.32 to 0.56) showed a superior ATE in reducing disability worsening and in disability improvement (HR=1.32, 95% CI=1.08 to 1.60). The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability. Conclusions The effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
MULTIPLE SCLEROSIS
STATISTICS
Megjelenés:Journal Of Neurology Neurosurgery And Psychiatry. - 94 : 12 (2023), p. 1004-1011. -
További szerzők:Malpas, Charles B. Sharmin, Sifat Roos, Izanne Horakova, Dana Kubala Havrdova, Eva Patti, Francesco Shaygannejad, Vahid Ozakbas, Serkan Eichau, Sara Onofrj, Marco Lugaresi, Alessandra Alroughani, Raed Prat, Alexandre Duquette, Pierre Terzi, Murat Boz, Cavit Grand'Maison, Francois Sola, Patrizia Ferraro, Diana Grammond, Pierre Yamout, Bassem Altintas, Ayse Gerlach, Oliver Lechner-Scott, Jeannette Bergamaschi, Roberto Karabudak, Rana Iuliano, Gerardo McGuigan, Christopher Cartechini, Elisabetta Hughes, Stella Sá, Maria José Solaro, Claudio Kappos, Ludwig Hodgkinson, Suzanne Slee, Mark Granella, Franco de Gans, Koen McCombe, Pamela Ampapa, Radek Walt, Anneke van der Butzkueven, Helmut Sanchez-Menoyo, Jose Vucic, Steve Laureys, Guy Sidhom, Youssef Gouider, Riadh Castillo Triviño, Tamara Gray, Orla Aguera-Morales, Eduardo Al-Asmi, Abdullah Shaw, Cameron Al-Harbi, Talal Csépány Tünde (1956-) (neurológus, pszichiáter) Sempere, Perez A. Trevino-Frenk, Irene Stuart, Elizabeth A. Kalincik, Tomas
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM107545
035-os BibID:(Scopus)85148460657 (WoS)000952991100026
Első szerző:Diouf, Ibrahima
Cím:Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis / Diouf Ibrahima, Malpas Charles B., Sharmin Sifat, Roos Izanne, Horakova Dana, Havrdova Eva Kubala, Patti Francesco, Shaygannejad Vahid, Ozakbas Serkan, Izquierdo Guillermo, Eichau Sara, Onofrj Marco, Lugaresi Alessandra, Alroughani Raed, Prat Alexandre, Girard Marc, Duquette Pierre, Terzi Murat, Boz Cavit, Grand'Maison Francois, Hamdy Sherif, Sola Patrizia, Ferraro Diana, Grammond Pierre, Turkoglu Recai, Buzzard Katherine, Skibina Olga, Yamout Bassem, Altintas Ayse, Gerlach Oliver, van Pesch Vincent, Blanco Yolanda, Maimone Davide, Lechner-Scott Jeannette, Bergamaschi Roberto, Karabudak Rana, Iuliano Gerardo, McGuigan Chris, Cartechini Elisabetta, Barnett Michael, Hughes Stella, Sa Maria José, Solaro Claudio, Kappos Ludwig, Ramo-Tello Cristina, Cristiano Edgardo, Hodgkinson Suzanne, Spitaleri Daniele, Soysal Aysun, Petersen Thor, Slee Mark, Butler Ernest, Granella Franco, de Gans Koen, McCombe Pamela, Ampapa Radek, Van Wijmeersch Bart, van der Walt Anneke, Butzkueven Helmut, Prevost Julie, Sinnige L. G. F., Sanchez-Menoyo Jose Luis, Vucic Steve, Laureys Guy, Van Hijfte Liesbeth, Khurana Dheeraj, Macdonell Richard, Gouider Riadh, Castillo-Trivino Tamara, Gray Orla, Aguera-Morales Eduardo, Al-Asmi Abdullah, Shaw Cameron, Deri Norma, Al-Harbi Talal, Fragoso Yara, Csepany Tunde, Perez Sempere Angel, Trevino-Frenk Irene, Schepel Jan, Moore Fraser, Kalincik Tomas
Dátum:2023
ISSN:1351-5101
Megjegyzések:Background This study assessed the effect of patient characteristics on the response to disease modifying therapy (DMT) in in multiple sclerosis (MS). Methods We extracted data from 61,810 patients from 135 centres across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS; follow-up ?1 year; ?3 EDSS scores; and with ?1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. Results Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio (HR)=0.52, 95%CI=0.45-0.60), 46% lower risk of disability worsening (HR=0.54, 95%CI=0.41-0.71) and 32% greater chance of disability improvement (HR=1.32, 95%CI=1.09-1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral MRI activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. Conclusions DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence attenuation of the effect of DMT with age.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Neurology. - 30 : 4 (2023), p. 1014-1024. -
További szerzők:Malpas, Charles B. Sharmin, Sifat Roos, Izanne Horakova, Dana Havrdova, Eva Patti, Francesco Shaygannejad, Vahid Ozakbas, Serkan Izquierdo, Guillermo Eichau, Sara Onofrj, Marco Lugaresi, Alessandra Alroughani, Raed Prat, Alexandre Girard, Marc Duquette, Pierre Terzi, Murat Boz, Cavit Grand'Maison, Francois Hamdy, Sherif Sola, Patrizia Ferraro, Diana Grammond, Pierre Turkoglu, Recai Buzzard, Katherine Skibina, Olga Yamout, Bassem Altintas, Ayse Gerlach, Oliver Pesch, Vincent van Blanco, Yolanda Maimone, Davide Lechner-Scott, Jeannette Bergamaschi, Roberto Karabudak, Rana Iuliano, Gerardo McGuigan, Christopher Cartechini, Elisabetta Barnett, Michael Hughes, Stella Sá, Maria José Solaro, Claudio Kappos, Ludwig Ramo-Tello, Cristina Cristiano, Edgardo Hodgkinson, Suzanne Spitaleri, Daniele Soysal, Aysun Petersen, Thor Slee, Mark Butler, Ernest Granella, Franco de Gans, Koen McCombe, Pamela Ampapa, Radek Wijmeersch, Bart Van Walt, Anneke van der Butzkueven, Helmut Prevost, Julie Sinnige, L. G. F. Sanchez-Menoyo, Jose Vucic, Steve Laureys, Guy Van Hijfte, Liesbeth Khurana, Dheeraj Macdonell, Richard Gouider, Riadh Castillo Triviño, Tamara Gray, Orla Aguera-Morales, Eduardo Al-Asmi, Abdullah Shaw, Cameron Deri, Norma Al-Harbi, Talal Fragoso, Yara Csépány Tünde (1956-) (neurológus, pszichiáter) Perez Sempere, Angel Trevino-Frenk, Irene Schepel, Jan Moore, Fraser Kalincik, Tomas
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM079822
Első szerző:Fekete Klára (neurológus)
Cím:Effectiveness and outcome of intravenous (IV) and intra-arterial (IA) thrombolysis in the Eastern Hungarian Stroke Center / K. Fekete, I. Fekete, D. Bereczki, T. Magyar, L. Olah, T. Csepany, L. Csiba
Dátum:2009
ISSN:1351-5101
Megjegyzések:Introduction: IV and IA thrombolysis is an effective treatment in acute ischemic stroke. Effectiveness and side effects were tested in the database. Methods: We treated 208 patients with IV/IA (145/63 pts) rt-PA after onset of ischemic stroke. After urgent CT, CTA we administered 0.9 mg/kg rt-PA according to the protocol. At local thrombolysis after 5 mg rt-PA bolus, 1 mg/min infusionwasadministered.GCS,NIHSSwereexaminedon the admission and after 7 days, mRS after 3 months. Risk factors and time window of stroke were estimated, too. Results: 64% of patients were male and 36% female.Time window was within 120min by 28% of patients, 180min 44%, 4.5h 17% and more than 270min 11% (for IA thrombolysis)afterstrokeonset.Averageagewas66.5?13.9 and 67.3?14.7 years.The most important risk factors were: hypertension (68.5%), atrial fibrillation (17%), other heart disorders(20%),smoking18.5%),diabetesmellitus(16%), hypercholesterolemia(19%),previousstrokeorTIA(16%). The average of NIHSS before thrombolysis was 14 (2-25), after 24 hours 11 (0-25). Hemorrhagic transformation was 13% after IA, 4.4% after IV administration of rt-PA. Intracerebral haemorrhage was recognized in 17.6% after IA,4.4%IV .Mortalitywas3%within24hours,21%within 3 months (IA: 27.9%, IV:13%). Large artery re-opening after IA thrombolysis was 46%. The proportion of independent patients was 36.4% (mRS) at 3 months. Conclusion: Beside IV thrombolysis IA administration of rt-PA is effective in acute stroke, but ICH and hemorrhagic transformation rate is more frequent
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
thrombolysis
Megjelenés:European Journal of Neurology. - 16 : Suppl. 3 (2009), p. 393. -
További szerzők:Fekete István (1951-) (neurológus, pszichiáter) Bereczki Dániel (1960-) (neurológus) Magyar T. Oláh László (1967-) (neurológus) Csépány Tünde (1956-) (neurológus, pszichiáter) Csiba László (1952-) (neurológus, pszichiáter)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM103012
035-os BibID:(Scopus)85102939985 (WOS)000631262400001
Első szerző:Hayden Zsófia
Cím:Clinical Characteristics and Outcome of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis Patients in a National Cohort / Hayden Zsófia, Bóné Beáta, Orsi Gergely, Szots Monika, Nagy Ferenc, Csépány Tünde, Mezei Zsolt, Rajda Cecília, Simon Diána, Najbauer József, Illes Zsolt, Berki Timea
Dátum:2021
ISSN:1664-2295
Megjegyzések:Background: In our previous single-center study of autoimmune encephalitis (AE) related autoantibody test results we found positivity in 60 patients out of 1,034 with suspected AE from 2012 through 2018 as part of a Hungarian nationwide program. In our current multicenter retrospective study, we analyzed the clinical characteristics and outcome of AE patients with positive neuronal cell surface autoantibody test results. Methods: A standard online questionnaire was used to collect demographic and clinical characteristics, laboratory and imaging data, therapy and prognosis of 30 definitive AE patients in four major clinical centers of the region. Results: In our study, 19 patients were positive for anti-NMDAR (63%), 6 patients (20%) for anti-LGI1, 3 patients for anti-GABABR (10%) and 3 patients for anti-Caspr2 (10%) autoantibodies. Most common prodromal symptoms were fever or flu-like symptoms (10/30, 33%). Main clinical features included psychiatric symptoms (83%), epileptic seizures (73%) and memory loss (50%). 19 patients (63%) presented with signs of central nervous system (CNS) inflammation, which occurred more frequently in elder individuals (p = 0.024), although no significant differences were observed in sex, tumor association, time to diagnosis, prognosis and immunotherapy compared to AE patients without CNS inflammatory markers. Anti-NMDAR encephalitis patients were in more severe condition at the disease onset (p = 0.028), although no significant correlation between mRS score, age, sex and immunotherapy was found. 27% of patients (n = 8) with associated tumors had worse outcome (p = 0.045) than patients without tumor. In most cases, immunotherapy led to clinical improvement of AE patients (80%) who achieved a good outcome (mRS ? 2; median follow-up 33 months). Conclusion: Our study confirms previous publications describing characteristics of AE patients, however, differences were observed in anti-NMDAR encephalitis that showed no association with ovarian teratoma and occurred more frequently among young males. One-third of AE patients lacked signs of inflammation in both CSF and brain MRI, which emphasizes the importance of clinical symptoms and autoantibody testing in diagnostic workflow for early introduction of immunotherapy, which can lead to favorable outcome in AE patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Neurology. - 12 (2021), p. 1-11. -
További szerzők:Bóné Beáta Orsi Gergely Szots Monika Nagy Ferenc (neurológus Kaposvár) Csépány Tünde (1956-) (neurológus, pszichiáter) Mezei Zsolt (1979-) (neurológus) Rajda Cecília Simon Diána Najbauer József Illés Zsolt (neurológus, Pécs) Berki Tímea
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM126269
035-os BibID:(scopus)85164541334 (wos)000999038400003
Első szerző:Kalincik, Tomas
Cím:Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis / Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, øivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven, Pamela McCombe, Olga Skibina, Jeannette Lechner-Scott, Barbara Willekens, Elisabetta Cartechini, Serkan Ozakbas, Raed Alroughani, Jens Kuhle, Francesco Patti, Pierre Duquette, Alessandra Lugaresi, Samia J. Khoury, Mark Slee, Recai Turkoglu, Suzanne Hodgkinson, Nevin John, Davide Maimone, Maria Jose Sa, Vincent van Pesch, Oliver Gerlach, Guy Laureys, Liesbeth Van Hijfte, Rana Karabudak, Daniele Spitaleri, Tunde Csepany, Riadh Gouider, Tamara Castillo-Trivino, Bruce Taylor, Basil Sharrack, John A. Snowden, MSBase Study Group Collaborators
Dátum:2023
ISSN:2168-6149 2168-6157
Megjegyzések:IMPORTANCE Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). OBJECTIVE To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. DESIGN, SETTING, AND PARTICIPANTS This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. EXPOSURE AHSCT vs fingolimod, natalizumab, or ocrelizumab. MAIN OUTCOMES Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. RESULTS Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; thematched groups were closely aligned. The proportion ofwomen ranged from65% to70%,and themean (SD)age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from0.77 (0.94) to0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated withmarginally lower ARR (mean [SD],0.08 [0.31]vs0.10 [0.34]), similar risk of disabilityworsening (HR, 1.06; 95% CI,0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%])were associatedwith similarARR (mean [SD],0.09 [0.34]vs0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). CONCLUSION In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
AHSCT
Fingolimod
Natalizumab
Ocrelizumab
multiple sclerosis
Megjelenés:JAMA Neurology. - 80 : 7 (2023), p. 702-713. -
További szerzők:Sharmin, Sifat Roos, Izanne Freedman, Mark S. Atkins, Harold Burman, Joachim Massey, Jennifer Sutton, Ian Withers, Barbara Macdonell, Richard Grigg, Andrew Torkildsen, øivind Bo, Lars Lehmann, Anne Kristine Kubala Havrdova, Eva Krasulova, Eva Trneny, Marek Kozak, Tomas Walt, Anneke van der Butzkueven, Helmut McCombe, Pamela Skibina, Olga Lechner-Scott, Jeannette Willekens, Barbara Cartechini, Elisabetta Ozakbas, Serkan Alroughani, Raed Kuhle, Jens Patti, Francesco Duquette, Pierre Lugaresi, Alessandra Khoury, Samia J. Slee, Mark Turkoglu, Recai Hodgkinson, Suzanne John, Nevin Maimone, Davide José Sá, Maria Pesch, Vincent van Gerlach, Oliver Laureys, Guy Van Hijfte, Liesbeth Karabudak, Rana Spitaleri, Daniele Csépány Tünde (1956-) (neurológus, pszichiáter) Gouider, Riadh Castillo Triviño, Tamara Taylor, Bruce V. Sharrack, Basil Snowden, John A. MSBase Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM103011
035-os BibID:(Scopus)85102090793 (Wos)000656637200025
Első szerző:Kalincik, Tomas
Cím:Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years / Kalincik Tomas, Diouf Ibrahima, Sharmin Sifat, Malpas Charles, Spelman Tim, Horakova Dana, Havrdova Eva Kubala, Trojano Maria, Izquierdo Guillermo, Lugaresi Alessandra, Prat Alexandre, Girard Marc, Duquette Pierre, Grammond Pierre, Jokubaitis Vilija, van der Walt Anneke, Grand'Maison Francois, Sola Patrizia, Ferraro Diana, Shaygannejad Vahid, Alroughani Raed, Hupperts Raymond, Terzi Murat, Boz Cavit, Lechner-Scott Jeannette, Pucci Eugenio, Van Pesch Vincent, Granella Franco, Bergamaschi Roberto, Spitaleri Daniele, Slee Mark, Vucic Steve, Ampapa Radek, McCombe Pamela, Ramo-Tello Cristina, Prevost Julie, Olascoaga Javier, Cristiano Edgardo, Barnett Michael, Saladino Maria Laura, Sanchez-Menoyo Jose Luis, Hodgkinson Suzanne, Rozsa Csilla, Hughes Stella, Moore Fraser, Shaw Cameron, Butler Ernest, Skibina Olga, Gray Orla, Kermode Allan, Csepany Tunde, Singhal Bhim, Shuey Neil, Piroska Imre, Taylor Bruce, Simo Magdolna, Sirbu Carmen-Adella, Sas Attila, Butzkueven Helmut, MSBase Study Group
Dátum:2021
ISSN:0028-3878 1526-632X
Megjegyzések:Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. Methods We studied patients from MSBase followed for ?1 year, with ?3 visits, ?1 visit per year, and exposed to MS therapy, and a subset of patients with ?15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. Results A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43?0.82, p = 0.0016), worsening of disability (0.56, 0.38?0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19?0.59, p = 0.00019). Among 1,085 patients with ?15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50?0.70, p = 10?9) and worsening of disability (0.81, 0.67?0.99, p = 0.043). Conclusion Continued treatment with MS immunotherapies reduces disability accrual by 19%?44% (95% CI 1%?62%), the risk of need of a walking aid by 67% (95% CI 41%?81%), and the frequency of relapses by 40?41% (95% CI 18%?57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. Classification of Evidence This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Neurology. - 96 : 5 (2021), p. e783-e797. -
További szerzők:Diouf, Ibrahima Sharmin, Sifat Malpas, Charles Spelman, Tim Horakova, Dana Havrdova, Eva Trojano, Maria Izquierdo, Guillermo Lugaresi, Alessandra Prat, Alexandre Girard, Marc Duquette, Pierre Grammond, Pierre Jokubaitis, Vilija Walt, Anneke van der Grand'Maison, Francois Sola, Patrizia Ferraro, Diana Shaygannejad, Vahid Alroughani, Raed Hupperts, Raymond Terzi, Murat Boz, Cavit Lechner-Scott, Jeannette Pucci, Eugenio Pesch, Vincent van Granella, Franco Bergamaschi, Roberto Spitaleri, Daniele Slee, Mark Vucic, Steve Ampapa, Radek McCombe, Pamela Ramo-Tello, Cristina Prevost, Julie Olascoaga, Javier Cristiano, Edgardo Barnett, Michael Saladino, Maria Laura Sanchez-Menoyo, Jose Hodgkinson, Suzanne Rózsa Csilla Hughes, Stella Moore, Fraser Shaw, Cameron Butler, Ernest Skibina, Olga Gray, Orla Kermode, Allan G. Csépány Tünde (1956-) (neurológus, pszichiáter) Singhal, Bhim Shuey, Neil Piroska Imre Taylor, Bruce V. Simó Magdolna Sirbu, Carmen-Adella Sas Attila Butzkueven, Helmut MSBase Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.